Rohan Palekar insider trades

Open-market stock purchases and sales by Rohan Palekar, Director at Neurogene Inc, from SEC Form 4 filings since Feb 1, 2010.

Track record: 67% of 6 scored buys are up 5% or more since purchase, averaging +64%.

Recent trades

DateStockTradeValue
Feb 20, 2026NGNE Neurogene IncBought (not open market)—
Oct 30, 2025ETNB 89bio, IncSold (not open market)—
Oct 30, 2025ETNB 89bio, IncSold (not open market)—
Oct 30, 2025ETNB 89bio, IncSold (not open market)—
Oct 30, 2025ETNB 89bio, IncSold (not open market)—
Oct 30, 2025ETNB 89bio, IncBought (not open market)—
Oct 30, 2025ETNB 89bio, IncSold (not open market)—
Oct 30, 2025ETNB 89bio, IncSold (not open market)—
Oct 30, 2025ETNB 89bio, IncSold (not open market)—
Oct 30, 2025ETNB 89bio, IncSold (not open market)—
Oct 30, 2025ETNB 89bio, IncSold (not open market)—

Companies traded

  • NGNE Neurogene Inc: other filings, last Feb 20, 2026
  • ETNB 89bio, Inc: 6 buys, 5 sales, last Oct 30, 2025
  • NLTX Neoleukin Therapeutics, Inc: other filings, last Jun 8, 2023
  • AVNR Avanir Pharmaceuticals, Inc: 3 buys, 3 sales, last Nov 28, 2014
  • MDVN Medivation, Inc: 4 sales, last Apr 20, 2011

Get free alerts when Rohan Palekar files a new trade →